GHRP-6

What is GHRP-6?

GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide structurally derived from enkephalin, an endogenous neuropeptide with opioid properties. It was one of the first non-GHRH GH secretagogues developed, and its research history dates back to Cyril Bowers’ laboratory in the 1970s-80s, where its study led to the discovery of the ghrelin receptor (GHS-R1a) decades before ghrelin itself was identified as its endogenous ligand.

GHRP-6 is the GH secretagogue with the greatest appetite-stimulating effect within its class, which is simultaneously its most distinctive characteristic and the primary factor differentiating its use from similar compounds such as GHRP-2 or Ipamorelin. This orexigenic (appetite-stimulating) effect is direct: GHRP-6 activates ghrelin receptors in the hypothalamus that specifically regulate energy balance and food intake, triggering an intense sensation of hunger typically reported 30-60 minutes after injection.

This characteristic, frequently considered an adverse effect, can become an advantage in certain research contexts: muscle mass gain protocols requiring caloric surplus, recovery from catabolic states, or situations where increased appetite is therapeutically desirable. In those scenarios, GHRP-6 offers advantages over alternatives with less ghrelinergic effect.

Mechanism of Action

GHRP-6 acts primarily as a potent agonist of the GHS-R1a receptor (growth hormone secretagogue receptor type 1a), which is the endogenous receptor for ghrelin. This action occurs at two levels:

At the pituitary level: Binding to GHS-R1a on somatotroph cells activates Gq protein, stimulates phospholipase C, and raises diacylglycerol and inositol triphosphate, causing a rapid increase in intracellular calcium and exocytosis of preformed GH vesicles. This is the central mechanism for acute GH release.

At the hypothalamic level: GHRP-6 activates hypothalamic GHRH neurons and simultaneously inhibits somatostatinergic neurons. This dual hypothalamic effect amplifies the pituitary response. Additionally, it activates the arcuate nucleus and ventromedial nucleus of the hypothalamus — the appetite control zones — explaining the potent orexigenic effect.

Comparison with GHRP-2: Both peptides act on the same receptor (GHS-R1a), but GHRP-6 has greater ghrelinergic efficacy in the hypothalamic orexigenic circuits. This translates into greater hunger but also, in some studies, slightly higher GH peaks at equivalent doses. The choice between GHRP-6 and GHRP-2 depends on the risk-benefit balance for the specific protocol.

Downstream effects documented in research include:

• GH increase: High-amplitude, short-duration peaks, with 3-10 fold elevations above baseline at 300-600 mcg doses.
• IGF-1 increase: Progressive elevation with continued use, mediating long-term anabolic and recovery effects.
• Tissue recovery improvement: Especially relevant in muscle and connective tissue, both directly (GHS-R1a receptors in muscle) and indirectly (via IGF-1).
• Cardioprotective effects: Several preclinical studies have identified GH-independent cardioprotective properties of GHRP-6, possibly related to reduction of oxidative stress and apoptosis in cardiomyocytes.

Reported Protocol

Standard reconstitution: 5 mg vial + 2.5 mL bacteriostatic water = 2 mg/mL (2000 mcg/mL). Each 0.1 mL contains 200 mcg.

Higher-frequency protocols report injections upon waking, pre-workout, and at bedtime. The fasted condition (minimum 2 hours without carbohydrate or protein intake) is critical: plasma insulin significantly reduces the GH response to secretagogues.

Classic reported stack: GHRP-6 + CJC-1295 No DAC. This combination is especially popular in pre-workout protocols, as it maximizes GH release during the peri-workout window, where synergy between exercise and secretagogues is greatest. The combination of 300 mcg GHRP-6 + 200-300 mcg CJC No DAC, administered 15-30 minutes before intense training, is among the most reported in research literature.

Reported Side Effects

• Intense appetite increase: GHRP-6’s most characteristic effect. It appears 30-60 minutes after injection and can be considerable, especially at high doses (>300 mcg/dose). This is the primary differentiating factor compared to GHRP-2.
• Water retention: More pronounced than with GHRP-2, related to higher GH and IGF-1 levels. May manifest as mild peripheral or facial edema.
• Elevated cortisol and prolactin at high doses: At doses above 300 mcg per injection, more significant cortisol and prolactin increases have been reported compared to GHRP-2. This effect attenuates at standard doses.
• Post-injection drowsiness: Especially with the nighttime dose, potentially desirable for improving sleep quality.
• Numbness and paresthesias: In extremities at high doses or with prolonged use.
• Reactive hypoglycemia: Especially during prolonged fasting or post-intense exercise.
• Lipohypertrophy: With repeated use at the same injection site.

Storage

• Lyophilized (powder): Store at -20°C, protected from light. Stable until indicated expiration date.
• Reconstituted: Store at 2-8°C. Stable for up to 30 days.
• Do not freeze the reconstituted solution.
• Rotate injection sites (abdomen, thigh, deltoid) to prevent lipohypertrophy.
• Use insulin syringe (0.3-1 mL) for precise dosing.
• Post-injection hunger should be anticipated by planning a meal for 45-60 minutes after the injection.

This content is for educational purposes only. Not medical advice. Always consult a healthcare professional before starting any research protocol.

Reported protocol (research reference)